Ran Pontifax (Israel) Iv, L... Net Worth

The estimated Net Worth of Ran Pontifax (Israel) Iv, L... is at least $8.5 million dollars as of 17 November 2020. Ran L owns over 60,000 units of Keros Therapeutics stock worth over $8,500,595 and over the last 4 years Ran sold KROS stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ran L KROS stock SEC Form 4 insiders trading

Ran has made over 1 trades of the Keros Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently Ran bought 60,000 units of KROS stock worth $3,000,000 on 17 November 2020.

The largest trade Ran's ever made was buying 60,000 units of Keros Therapeutics stock on 17 November 2020 worth over $3,000,000. On average, Ran trades about 60,000 units every 0 days since 2020. As of 17 November 2020 Ran still owns at least 155,262 units of Keros Therapeutics stock.

You can see the complete history of Ran L stock trades at the bottom of the page.

Insiders trading at Keros Therapeutics

Over the last 5 years, insiders at Keros Therapeutics have traded over $50,765,607 worth of Keros Therapeutics stock and bought 2,504,088 units worth $46,191,339 . The most active insiders traders include Ran Nussbaum, Carl L Gordon et Tomer Kariv. On average, Keros Therapeutics executives and independent directors trade stock every 25 days with the average trade being worth of $3,312,649. The most recent stock trade was executed by Carl L Gordon on 13 August 2024, trading 250,000 units of KROS stock currently worth $11,002,500.

What does Keros Therapeutics do?

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Complete history of Ran L stock trades at Keros Therapeutics

Keros Therapeutics executives and stock owners

Keros Therapeutics executives and other stock owners filed with the SEC include:

• Dr. Jasbir Seehra Ph.D.,
  Pres, CEO, Treasurer, & Director
• Dr. Jennifer Lachey Ph.D.,
  Chief Scientific Officer
• Keith C. Regnante,
  Chief Financial Officer
• Christopher Rovaldi M.Sc.,
  Chief Operating Officer
• Dr. Simon Cooper MBBS,
  Chief Medical Officer
• Robin Wagner,
  VP of HR
• Esther Cho J.D.,
  Head of Legal & Corp. Sec.
• Julius Knowles,
  
• Tomer Kariv,
  
• Carl L Gordon,
  Director
• Ran Nussbaum,
  
• Nima Farzan,
  
• Tomer Pontifax (Israel) Iv,...,
  
• Mary Ann Gray,
  
• Ran Pontifax (Israel) Iv, L...,
  
• Alpna Seth,
  
• Keith Regnante,
  CHIEF FINANCIAL OFFICER
• Jasbir Seehra,
  CHIEF EXECUTIVE OFFICER
• Christopher Rovaldi,
  CHIEF OPERATING OFFICER
• Jennifer Lachey,
  Chief Scientific Officer
• Claudia Ordonez,
  Chief Medical Officer
• Alon Lazarus,
  Director
• Advisors Llc Orbi Med Capit...,
  
• Management 4 G.P. (2015) Lt...,
  
• Bio Ventures Limited Partne...,
  
• Simon Peter Cooper,
  CHIEF MEDICAL OFFICER
• Jean Jacques Bienaime,